The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Dezaguanina     3-amino-4,7,9- triazabicyclo[4.3.0]nona- 2,7...

Synonyms: Dezaguanine, Dezaguaninum, SureCN4184, CHEMBL31882, CI-809, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CI 908


High impact information on CI 908

  • 3-Deazaguanine inhibited both DNA and protein synthesis, and both log DNA synthesis and log protein synthesis correlated inversely with [3-deazaguanine] X t and directly with cell viability (P less than 0.001) [6].
  • These data suggest that 3-deazaguanine is anabolized and incorporated into DNA, and that this incorporation is related to decreased DNA synthesis and cell death [6].
  • Cell line TGR-3, deficient in hypoxanthine-guanine phosphoribosyltransferase (EC and resistant to 3-deazaguanine, also formed both metabolites [7].
  • A new synthesis of certain 7-(beta-D-ribofuranosyl) and 7-(2-deoxy-beta-D-ribofuranosyl) derivatives of 3-deazaguanine via the sodium salt glycosylation procedure [8].
  • The G to 3DG substitution at the primer terminus also decreased the formation of correct base pairs as well as incorrect base pairs [9].

Chemical compound and disease context of CI 908


Biological context of CI 908


Anatomical context of CI 908


Associations of CI 908 with other chemical compounds


Gene context of CI 908


Analytical, diagnostic and therapeutic context of CI 908


  1. Action of 3-deazaguanine in Escherichia coli. Saunders, P.P., Chao, L.Y., Robins, R.K., Loo, T.L. Mol. Pharmacol. (1979) [Pubmed]
  2. Antirhinovirus activity of purine nucleoside analogs. De Clercq, E., Bernaerts, R., Bergstrom, D.E., Robins, M.J., Montgomery, J.A., Holy, A. Antimicrob. Agents Chemother. (1986) [Pubmed]
  3. Synthesis of arabinofuranosyl derivatives of 3-deazaguanine. Poonian, M.S., McComas, W.W., Kramer, M.J. J. Med. Chem. (1979) [Pubmed]
  4. Inhibition of bluetongue and Colorado tick fever orbiviruses by selected antiviral substances. Smee, D.F., Sidwell, R.W., Clark, S.M., Barnett, B.B., Spendlove, R.S. Antimicrob. Agents Chemother. (1981) [Pubmed]
  5. 3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicity. Margolin, K., Doroshow, J., Leong, L., Akman, S., Carr, B., Odujinrin, O., Flanagan, B., Grove, W., DeLap, R., Goldberg, D. Investigational new drugs. (1990) [Pubmed]
  6. Correlation of biochemical effects and incorporation of 3-deazaguanine into nucleic acids to cytotoxicity in L1210 cells. Pieper, R.O., Barrows, L.R., Mandel, H.G. Cancer Res. (1986) [Pubmed]
  7. 3-Deazaguanosine is metabolized to the triphosphate derivative in Chinese hamster cells deficient in hypoxanthine-guanine phosphoribosyltransferase. Saunders, P.P., Tan, M.T., Spindler, C.D., Robins, R.K., Plunkett, W. J. Biol. Chem. (1986) [Pubmed]
  8. A new synthesis of certain 7-(beta-D-ribofuranosyl) and 7-(2-deoxy-beta-D-ribofuranosyl) derivatives of 3-deazaguanine via the sodium salt glycosylation procedure. Gupta, P.K., Robins, R.K., Revankar, G.R. Nucleic Acids Res. (1985) [Pubmed]
  9. Fidelity of mispair formation and mispair extension is dependent on the interaction between the minor groove of the primer terminus and Arg668 of DNA polymerase I of Escherichia coli. McCain, M.D., Meyer, A.S., Schultz, S.S., Glekas, A., Spratt, T.E. Biochemistry (2005) [Pubmed]
  10. Dezaguanine mesylate: a new antipurine antimetabolite. Leopold, W.R., Fry, D.W., Boritzki, T.J., Besserer, J.A., Pattison, I.C., Jackson, R.C. Investigational new drugs. (1985) [Pubmed]
  11. Clinical pharmacokinetics of 3-deazaguanine. Pendyala, L., Creaven, P.J., Whitfield, L.R. Cancer Chemother. Pharmacol. (1991) [Pubmed]
  12. Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Kawana, F., Shigeta, S., Hosoya, M., Suzuki, H., De Clercq, E. Antimicrob. Agents Chemother. (1987) [Pubmed]
  13. Effects of 3-deazaguanosine and 3-deazaguanine on the growth and maturation of the human promyelocytic leukemia cell line, HL-60. Lucas, D.L., Chiang, P.K., Webster, H.K., Robins, R.K., Wiesmann, W.P., Wright, D.G. Adv. Exp. Med. Biol. (1984) [Pubmed]
  14. Synthesis of 8-amino-3-deazaguanine via imidazole precursors. Antitumor activity and inhibition of purine nucleoside phosphorylase. Berry, D.A., Gilbertsen, R.B., Cook, P.D. J. Med. Chem. (1986) [Pubmed]
  15. The effects of 3-deazaguanine on Rous sarcoma virus transformation. Chen, Y.C., Liu, L.A., Borchardt, K.A. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi (1990) [Pubmed]
  16. DNA-directed actions of 3-deazaguanine: effects on DNA integrity and DNA elongation/ligation. Pieper, R.O., Kennedy, K.A., Mandel, H.G. Cancer Res. (1988) [Pubmed]
  17. Determination of 3-deazaguanine in mice plasma by high-performance liquid chromatography. Chandrasekaran, B., Ardalan, B. J. Chromatogr. (1984) [Pubmed]
  18. 3-deazaguanine, a candidate drug for the chemotherapy of breast carcinomas? Khwaja, T.A. Cancer treatment reports. (1982) [Pubmed]
WikiGenes - Universities